Multidisciplinary management of endocrinopathies and treatment-related toxicities in patients with Bloom syndrome and cancer.
Carolyn Fein LevyLubaina S PresswalaAlana SlomovicJessica StiefelRifka Schulman-RosenbaumPublished in: Pediatric blood & cancer (2020)
The treatment of malignancy in cancer predisposition syndromes that also confer exquisite sensitivity to standard chemotherapy and radiation regimens remains a challenge. Bloom syndrome is one such disorder that is caused by a defect in DNA repair, predisposing to the development of early-onset age-related medical conditions and malignancies. We report on two patients with Bloom syndrome who responded well to chemotherapy despite significant alterations to standard protocols necessitated by hypersensitivity. Both patients experienced severe toxicities and exacerbation of endocrine comorbidities during chemotherapy. A multidisciplinary team of oncologists and endocrinologists is best suited to care for this patient population.
Keyphrases
- early onset
- dna repair
- case report
- papillary thyroid
- healthcare
- quality improvement
- palliative care
- locally advanced
- late onset
- dna damage
- chronic obstructive pulmonary disease
- newly diagnosed
- squamous cell
- radiation therapy
- drug induced
- dna damage response
- chronic kidney disease
- extracorporeal membrane oxygenation
- lymph node metastasis
- mechanical ventilation
- affordable care act
- chronic pain